Abstract

Ever since early 2020, the uncontrolled pandemic of COVID-19 has been causing a havoc globally with intermittent waxing and waning. The end is nowhere in sight. The scientists have done a commendable job in developing vaccines against the causative virus of COVID-19 in a record time frame of less than one year after identification of the virus. Since the safety of paediatric population meris an extra vigilance, the work on vaccines for children started after the vaccines for adults were successfully developed and tested. Today, Pfizer NBio Tech vaccine for children05 through 18 years) has emerged as the first in the category and its use has kick started. China’s SinoVac is being used in such other countries as UAE and Indonesia. India’s Covaxin stands incorporated in the national program for actual inoculation of adolescents aged 15-18 years. Effective March 2022, it shall be employed for children between 12 and 15 years. Additionally, Zydus Healthcare’s ZyCoV-D, meant for children above 12 years of age stands approved for emergency use in children Endeavours aimed at vaccination of all children need to be intensified for winning the war against the ongoing COVID-19 pandemic. By all yardsticks, it is unlikely to be wiped out and is all set to stay as an endemic. Just like influenza!

Keywords

ZyCoV-D